Please ensure Javascript is enabled for purposes of website accessibility

How Fishy Is This Fish Oil Pill?

By Taylor Carmichael - Oct 2, 2019 at 4:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Amarin's Vascepa just might be a blockbuster.

The Irish biotech Amarin (AMRN -1.75%) only has one drug, but it's a doozy. Vascepa is a purified form of fish oil extract, without DHA and other components. What is left behind is 1 gram of the omega-3 fatty acid EPA. It's this fishy fatty acid that does all the work in reducing a type of human fat known as triglycerides.

While everyone has heard of cholesterol, triglycerides are arguably just as important. Healthy people have a count of less than 150 milligrams per deciliter. Anything over 200 mg/dl is high -- and dangerous. In 2012, the FDA approved Vascepa as a drug that lowers your triglyceride count. But what's really exciting people is the Harvard study that was completed last year.

Image of a Vascepa pill

Source: Amarin.

It was a massive five-year trial, involving 8,179 people with triglyceride levels from 150 to 499. The researchers' conclusion astounded a lot of people: "Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 grams of (Vascepa) twice daily than among those who received placebo."

To be specific, this means the people in the study who were taking Vascepa had a 25% reduction in the risk of heart attacks, strokes, and death. Amarin's drug reduced heart attacks by 31%, it reduced strokes by 28%, and it reduced cardiovascular death by 20%. As Dr. Deepak Bhatt, professor of medicine at Harvard University, put it, "This may be the biggest development in cardiovascular prevention since statins."

Heart disease is the No. 1 killer of human beings. It kills more people than all the cancers combined. To have a new drug that dramatically reduces the risk of heart attacks, strokes, and deaths is wonderful, but also rather shocking. And for this drug to be modified from fish oil? For a lot of people, it's mind-boggling.

The New York Times found a lot of doctors who were shocked at this study. "I'm very surprised by the magnitude of the results, which quite frankly are large," said Dr. Michael J. Blaha of Johns Hopkins. And Dr. Ethan Weiss, a cardiologist at the University of California, San Francisco, said, "This is really big, and I was wrong. And I am happy I was wrong, and I'm excited we have a new pathway and set of tools to explore for our patients."

How big is this market?

Medical science has always focused on lowering cholesterol to prevent heart disease. The drugs that do this are called statins. It's a $19 billion market. But what if your triglyceride count is just as important as your cholesterol count? One-third of adults in the United States have high triglycerides. That's approximately 70 million people. The market for lowering your cholesterol sits at $69 billion. It's possible this drug is at least a $10 billion market opportunity for Amarin. 

Competitive therapeutic options are not very good. A drug class known as fibrates has been linked to liver damage. Doctors sometimes prescribe statins, which are designed to reduce cholesterol, not triglycerides. Everyone in the Harvard study was on statin medication. The people on statins were 31% more likely to have a heart attack than the people who were on statins and Vascepa, 28% more likely to have a stroke, and 20% more likely to be dead. Clearly statins do not help much with triglycerides. 

The other competitive therapy is fish oil, which has never worked for anybody. The DHA in fish oil actually has some negative effects. The generic form of fish oil (trademarked Lovaza) carries an FDA warning that it might cause atrial fibrillation (heart flutter). 

A shocking opportunity

Amarin's stock price quadrupled after the study was announced. That sharp increase underestimates how big this news is. Vescepa has already been approved by the FDA as a safe and effective way to reduce your triglycerides. What the Harvard study shows is just how important it is to do just that. The implication from the numbers is that a high triglyceride count can itself result in heart attacks, strokes, and deaths. 

Some skeptics are suggesting that it's the placebo that killed those people. The placebo -- a mineral oil that was approved by the FDA in the trial design -- has never been linked to heart attacks, strokes, or deaths in the past. What's far more likely is that people criticizing the Harvard study are having trouble wrapping their heads around a new understanding of heart disease.

Your triglyceride count is important, perhaps as important as your cholesterol numbers. Whether the FDA will allow Amarin to expand its label and acknowledge this truth is an open question. Clearly this company and its wonder drug have ruffled a lot of feathers. Investors in the healthcare space will need to consider their appetite for risk before moving Amarin into a portfolio.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
AMRN
$1.41 (-1.75%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.